Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Doris K. Hansen · SciRah

Researcher profile · Semantic Scholar

Doris K. Hansen

Share profile

Doris K. Hansen — researcher profile on SciRah

h-index: 22
Works: 225
Citations: 2,077

Most-cited papers

A Comparison of Standard of Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Doris K. Hansen, Lauren C. Peres, D. Dima, Alicia Richards +48 more
2025Journal of Clinical Oncology48 citations
Semantic Scholar
Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy.
B. Dhakal, O. Akhtar, D. Fandrei, Alexandria M. Jensen +39 more
2025Blood38 citations
Semantic Scholar
Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.
S. Sidana, Nausheen Ahmed, O. Akhtar, R. Brazauskas +22 more
2025Blood31 citations Open access
Semantic Scholar
Real-World Experience with Teclistamab for Relapsed/ Refractory Multiple Myeloma from the U.S. Myeloma Immunotherapy Consortium.
Beatrice M Razzo, S. Midha, A. Portuguese, A. Grajales-Cruz +42 more
2025Blood Cancer Discovery22 citations
Semantic Scholar
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
D. Dima, Mariola A. Vazquez-Martinez, James A. Davis, Utkarsh Goel +40 more
2025Blood Cancer Journal21 citations Open access
Semantic Scholar
Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma
T. Tix, Mohammad Alhomoud, R. Shouval, G. Iacoboni +7 more
2025Molecular Therapy17 citations Open access
Semantic Scholar
Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma
Mobina Golmohammadi, S. Raza, Maram Albayyadhi, Hossein Sholehrasa +11 more
2025Blood Cancer Journal16 citations Open access
Semantic Scholar
Managing IEC-associated enterocolitis following CAR-T therapy in multiple myeloma
R. Banerjee, H. Hosoya, Lekha Mikkilineni, Doris K. Hansen +2 more
2025Blood Cancer Journal15 citations Open access
Semantic Scholar
Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel
Satabdi Saha, Lubna Rehman, Abdur Rehman, F. Darbaniyan +22 more
2025Blood Advances13 citations Open access
Semantic Scholar
Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment
D. Dima, Aimaz Afrough, Utkarsh Goel, A. Grajales-Cruz +40 more
2025Blood Advances13 citations Open access
Semantic Scholar
CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.
D. Dima, Rahul Banerjee, Doris K. Hansen
2025Hematology. American Society of Hematology. Education Program12 citations
Semantic Scholar
Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study
O. Akhtar, Temitope Oloyede, R. Brazauskas, Aimaz Afrough +23 more
2024Blood Advances12 citations Open access
Semantic Scholar
Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia
Gliceida M. Galarza Fortuna, Lauren C. Peres, Elena Nazarenko, Andre De Menezes Silva Corraes +32 more
2025Blood Advances10 citations
Semantic Scholar
Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality
S. Sidana, Brett Reid, D. Dima, Lauren C. Peres +62 more
2025Blood10 citations
Semantic Scholar
Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study
S. Richard, Mahmoud R. Gaballa, T. Gregory, Saurabh Chhabra +16 more
2025Blood9 citations
Semantic Scholar
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
O. Pasvolsky, D. Dima, Lei Feng, Wen-Li Dong +47 more
2025Blood Cancer Journal9 citations Open access
Semantic Scholar
Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma
Francesco Maura, Ciara L. Freeman, Holly Lee, K. Maclachlan +32 more
2024Blood9 citations
Semantic Scholar
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium
A. Portuguese, James A. Davis, S. Raza, O. Castaneda Puglianini +38 more
2026Blood Cancer Journal7 citations Open access
Semantic Scholar
Cytopenias and infections following ciltacabtagene autoleucel in heavily pretreated relapsed or refractory multiple myeloma
D. Dima, J. Logue, Syed Hamza Bin Waqar, Lauren C. Peres +29 more
2025Haematologica7 citations Open access
Semantic Scholar
Real-world outcomes with elranatamab in multiple myeloma: A multi-center analysis from the United States multiple myeloma immunotherapy consortium
A. Portuguese, James A. Davis, S. Raza, O. Castaneda Puglianini +35 more
2025Blood7 citations
Semantic Scholar
Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma
Stefanie Palfi, Lauren C. Peres, Himara Koelmeyer, M. Alsina +22 more
2025Blood Cancer Journal6 citations Open access
Semantic Scholar
Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy Consortium.
K. Sweiss, Charlotte B. Wagner, Eric Anto, Tom Greene +26 more
2025Transplantation and Cellular Therapy6 citations Open access
Semantic Scholar
Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma
Doris K. Hansen, Brett Reid, A. Grajales-Cruz, Peter Cheng +31 more
2025Blood6 citations
Semantic Scholar
Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study
Doris K. Hansen, Danai Dima, H. Mian, Jakob Devos +26 more
2026Blood Cancer Journal5 citations
Semantic Scholar
Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary disease
Ziad Abuhelwa, F. Amisha, Wenyi Fan, Gabriel De Avila +11 more
2025Frontiers in Oncology5 citations Open access
Semantic Scholar
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience
Aimaz Afrough, D. Dima, Beatrice M Razzo, Utkarsh Goel +42 more
2025Blood Cancer Journal5 citations Open access
Semantic Scholar
Demystifying the diagnosis and management of ICUS, CHIP, and CCUS.
Zhuo-Er Xie, D. Lee, Doris K. Hansen, S. Loghavi
2025Hematology. American Society of Hematology. Education Program4 citations
Semantic Scholar
Dexamethasone for management of cytokine release syndrome (CRS) associated with talquetamab in patients with Relapsed/Refractory multiple myeloma
Jessica McElwee, Grace Elsey, R. Gonzalez, Kelley L. Julian +22 more
2025Blood4 citations
Semantic Scholar
Suppressive dexamethasone (SupDex) to prevent delayed non-icans delayed neurotoxicity (DNT) post ciltacabtagene-autoleucel(cilta-cel) in patients with relapsed myeloma.suppressive dexamethasone (SupDex) to prevent delayed non-icans delayed neurotoxicity (DNT) post ciltacabtagene-autoleucel(cilta-cel
Karla Feliciano-Salva, Christina Copponex, Junmin Whiting, Doris K. Hansen +11 more
2025Blood4 citations
Semantic Scholar
Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysis
H. Mian, M. Faisal, Tie-Ning Chen, R. Brazauskas +28 more
2025Blood3 citations
Semantic Scholar
Outcomes of stem cell boost (SCB) versus supportive care alone for prolonged cytopenias after chimeric antigen receptor T cell therapy (CAR-T) in relapsed/refractory multiple myeloma (RRMM): A muli-center real-world analysis
Cindy Varga, Myra Robinson, James A. Davis, Hamza Hashmi +25 more
2025Blood3 citations
Semantic Scholar
The Real‐World Safety and Efficacy of Bispecific T‐Cell Engager Therapy in Systemic AL Amyloidosis
M. Rees, Jack Khouri, A. Grajales-Cruz, S. Zanwar +22 more
2025American journal of hematology/oncology3 citations
Semantic Scholar
Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia
Mahmoud R. Gaballa, Kelley L. Julian, Aimaz Afrough, Doris K. Hansen +47 more
2026Blood Advances2 citations Open access
Semantic Scholar
Expanded antigen-specific donor regulatory T cells for GVHD prevention.
J. Pidala, N. Cieri, M. Schell, Xiao-Fei Song +34 more
2026Blood2 citations
Semantic Scholar
ASTCT Consensus Grading for Toxicities after Immune Effector Cell Therapy.
M. Perales, Jorg Dietrich, Juliane Gust, B. Santomasso +32 more
2026Transplantation and Cellular Therapy2 citations Open access
Semantic Scholar
Plasma cell identity escape drives resistance to anti-BCMA T-cell–redirecting therapy in multiple myeloma
Francesco Maura, Ciara L. Freeman, K. Maclachlan, Marta Larrayoz Ilundain +42 more
2025bioRxiv2 citations
Semantic Scholar
The real-world safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy in systemic AL amyloidosis
Matthew J. Rees, Raffaella Cassano Cassano, Melinda S. Y. Tan, Eli Zolotov +24 more
2025Blood2 citations
Semantic Scholar
Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia.
Eric E. Gaskill, O. Albanyan, S. Naqvi, Q. Mo +14 more
2025Transplantation and Cellular Therapy2 citations
Semantic Scholar
Enhanced CAR-T Function and Mitochondrial Fitness from Earlier Unfractionated Stem Cell Product in Multiple Myeloma.
Ciara L. Freeman, Julieta Abraham-Miranda, M. Menges, R. Atkins +15 more
2025Molecular Therapy2 citations Open access
Semantic Scholar
Real-world incidence and management of non-icans neurologic events following ciltacabtagene autoleucel in multiple myeloma
Doris K. Hansen, O. Castaneda Puglianini, A. Grajales-Cruz, Saurabh P. Nagar +12 more
2025Blood2 citations
Semantic Scholar
Outcomes of bispecific T-cell engagers in MM patients with central nervous system (CNS) involvement
Mahmoud R. Gaballa, Lei Feng, Aimaz Afrough, Rahul Banerjee +40 more
2025Blood2 citations
Semantic Scholar
Talquetamab outcomes in relapsed/refractory myeloma with extramedullary and paraskeletal soft tissue plasmacytomas
Aimaz Afrough, O. Pasvolsky, S. Zanwar, Mahmoud R. Gaballa +49 more
2025Blood2 citations
Semantic Scholar
CD40 Ligand Blockade for Prevention of Graft-Versus-Host Disease
F. Khimani, H. Ali, Jongphil Kim, Christopher L Cubitt +22 more
2025JCO Oncology Advances2 citations Open access
Semantic Scholar
Real world outcomes of bispecific T-cell engagers in plasma cell leukemia
Mahmoud R. Gaballa, Kelley L. Julian, Aimaz Afrough, Doris K. Hansen +42 more
2025Blood2 citations
Semantic Scholar
Beyond chip: Ccrs predicts prolonged cytopenias and inferior survival following anti-BCMA CAR-T in multiple myeloma
Zhuo-Er Xie, O. Castaneda Puglianini, T. Nishihori, A. Grajales-Cruz +30 more
2025Blood2 citations
Semantic Scholar
Talquetamab for relapsed/refractory multiple myeloma : Real-world outcomes from the US multiple myeloma immunotherapy consortium
O. Pasvolsky, A. Grajales-Cruz, Doris K. Hansen, Lei Feng +48 more
2025Blood2 citations
Semantic Scholar
Supportive care alone is effective for managing low-grade CRS in multiple myeloma patients treated with bispecific antibodies
Victoria R Nachar, Iman Ahmed, Matthew J. Pianko, E. Campagnaro +25 more
2025Blood2 citations
Semantic Scholar
Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival
G. Kaur, Jennifer Logue, R. Brazauskas, Temitope Oloyede +27 more
2026Transplantation and Cellular Therapy1 citations Open access
Semantic Scholar
Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple Myeloma.
H. Hosoya, Arash Velayati, Danai Dima, Alexandria Jensen +24 more
2026Blood1 citations
Semantic Scholar
Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)—real world experience from the US multiple myeloma immunotherapy consortium
Cindy Varga, Myra Robinson, James A. Davis, H. Hashmi +24 more
2026Blood Cancer Journal1 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Sidana×27
Invite
S. Sidana — researcher profile on SciRah
A. Grajales-Cruz×25
Invite
A. Grajales-Cruz — researcher profile on SciRah
Aimaz Afrough×24
Invite
Aimaz Afrough — researcher profile on SciRah
Larry D. Anderson×24
Invite
Larry D. Anderson — researcher profile on SciRah

×23

Invite

D. Sborov — researcher profile on SciRah

Invite

D. Dima — researcher profile on SciRah

Jack Khouri×22

Invite

Jack Khouri — researcher profile on SciRah

Ciara L. Freeman×21

Invite

Ciara L. Freeman — researcher profile on SciRah

Leyla Shune×20

Invite

Leyla Shune — researcher profile on SciRah

Mahmoud R. Gaballa×20

Invite

Mahmoud R. Gaballa — researcher profile on SciRah

James A. Davis×20

Invite

James A. Davis — researcher profile on SciRah

O. Castaneda Puglianini×19

Invite

O. Castaneda Puglianini — researcher profile on SciRah